Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial

Vaccine

Volumn 32, Issue 13, 2014, Pages 1480-1487

  Tinoco, Juan Carlos ^a   Pavia Ruz, Noris ^b   Cruz Valdez, Aurelio ^c   Aranza Doniz, Carlos ^d   Chandrasekaran, Vijayalakshmi ^e   Dewé, Walthère ^f   Liu, Aixue ^e   Innis, Bruce L ^e   Jain, Varsha K ^e  

^a Hospital General de Durango   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^d Secretaria de Salud del Estado de Mexico   (Mexico)

^e GLAXOSMITHKLINE   (United States)

^f GSK   (Belgium)

Author keywords

Inactivated quadrivalent influenza vaccine; Seasonal influenza; Victoria lineage; Yamagata lineage

Indexed keywords

INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE; TRIVALENT INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA B; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; MYALGIA; NORMAL HUMAN; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; RHINOPHARYNGITIS; SEASONAL INFLUENZA; SEROCONVERSION; SHIVERING; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

INACTIVATED QUADRIVALENT INFLUENZA VACCINE; SEASONAL INFLUENZA; VICTORIA LINEAGE; YAMAGATA LINEAGE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84896733461     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.022     Document Type: Article

References (20)

1. Fiore A.E., Uyeki T.M., Broder K., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.
2. Thompson W.W., Shay D.K., Weintraub E., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
3. Ambrose C.S., Levin M.J. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012, 8:81-88.
4. Irving S.A., Patel D.C., Kieke B.A., et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses 2012, 6:37-43.
5. United States Centers for Disease Control and Prevention Seasonal influenza activity surveillance reports: 2000-2001 to 2009-2010 seasons 2010, http://www.cdc.gov/flu/weekly/pastreports.htm [accessed 31 January 2014].
6. Belongia E.A., Kieke B.A., Donahue J.G., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199:159-167.
7. Bridges C.B., Thompson W.W., Meltzer M.I., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000, 284:1655-1663.
8. Lo Y.C., Chuang J.H., Kuo H.W., et al. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 season. PLoS One 2013, 8:e58222.
9. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30:1993-1998.
10. World Health Organization Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season 2012, http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf [accessed 31 January 2014].
11. Centers for Disease Control and Prevention Interim recommendations: prevention and control of Influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) 2013, http://www.cdc.gov/flu/professionals/acip/2013-interim-recommendations.htm [accessed 31 January 2014].
12. Block S.L., Falloon J., Hirschfield J.A., et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012, 31:745-751.
13. Sheldon E.A., Jeanfreau R., Sliman J.A., et al. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study. Influenza Other Respir Viruses 2013, 7:1142-1150.
14. Domachowske J.B., Pankow-Culot H., Bautista M., et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013, 207:1878-1887.
15. Langley J.M., Carmona Martinez A., Chatterjee A., et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013, 208:544-553.
16. Kieninger D., Sheldon E., Lin W.Y., et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >=18 years. BMC Infect Dis 2013, 13:343.
17. Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013, 31:770-776.
18. Hehme N., Künzel W., Petschke F., et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002, 22:751-769.
19. US Food and Drug Administration Guidance for Industry Clinical data needed to support the licensure of pandemic influenza vaccines May 2007, http://www.fda.gov/cber/gdlns/panfluvac.htm [accessed 31 January 2014].
20. World Health Organization Summary review of the 2010-2011 northern hemisphere winter influenza season 2011, http://www.who.int/influenza/2010_2011_seasonal_review_mexico_usa_canada_main.jpg [accessed 31 January 2014].